Danaher said total sales in 2025 increased 3.0% compared with 2024, and core sales increased 2.0%. The company said the increase in core sales was led primarily by the Biotechnology segment, with a lesser contribution from the Diagnostics segment, partially offset by the Life Sciences segment.

1. 01

   Danaher said total sales in 2025 increased 3.0% compared with 2024, and core sales increased 2.0%. The company said the increase in core sales was led primarily by the Biotechnology segment, with a lesser contribution from the Diagnostics segment, partially offset by the Life Sciences segment.

2. 02

   Danaher said net earnings from continuing operations for 2025 totaled approximately $3.6 billion, or $5.03 per diluted common share, compared with approximately $3.9 billion, or $5.29 per diluted common share, for 2024. The company cited intangible asset impairments, increased other expenses and decreased interest income as factors in the decline.

3. 03

   Danaher said operating profit margins declined 130 basis points from 20.4% in 2024 to 19.1% in 2025. The company said impairment charges related to trade names, technology, other intangible assets and facilities in 2025, net of impairment charges related to trade names in 2024, had an impact of 120 basis points.

4. 04

   Danaher said operating cash flow from continuing operations for 2025 totaled approximately $6.4 billion, a decrease of $272 million, or 4%, compared with 2024. The company said cash and cash equivalents as of December 31, 2025 totaled approximately $4.6 billion.

Key figures

Fiscal year ended December 31, 2025

Revenue

$24.6B

Operating income

$4.7B

Net income

$3.6B

EPS

$5.05

Gross profit

$14.5B

Operating cash flow

$6.4B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.